Eric Faulkner, RTI Health Solutions Director of US Market Access and Reimbursement, will speak at the Oncology Biomarkers: From Discovery to Validation Conference
to be held in San Francisco, California on January 14-15, 2008. The conference will cover a wide range of topics, including innovative techniques for discovering and validating oncology biomarkers, current and emerging clinical applications of oncology biomarkers and discussion of key regulatory and reimbursement issues related to use of biomarkers to inform use of targeted cancer therapies.
Mr. Faulkner will lead a discussion entitled Clinical Designs for Reimbursement and participate in a panel on Reimbursement and Regulatory Approaches to Biomarker Discovery and Validation with other US regulatory and reimbursement experts.
Mr. Faulkner’s responsibilities at RTI Health Solutions (RTI-HS) involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and is serving as a lead editor for an upcoming book entitled Medical Device and Diagnostics Outcomes Research: Issues and Good Research Practices, sponsored by the US Medical Device and Diagnostics Council of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
In addition to responsibilities at RTI, Mr. Faulkner also serves as Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology.
Please contact Mr. Faulkner if you plan to attend the conference and would like to pre-arrange a meeting.